X0202 SCHEDULE 13G 0001273087 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 02/24/2026 0001829802 Sensei Biotherapeutics, Inc. 81728A207 1405 Research Boulevard, Suite 125 Rockville MD 20850 Rule 13d-1(c) ICS Opportunities II LLC E9 0.00 127917.00 0.00 127917.00 127917.00 N 9.5 OO Millennium Management LLC DE 0.00 128761.00 0.00 128761.00 128761.00 N 9.6 OO Millennium Group Management LLC DE 0.00 128761.00 0.00 128761.00 128761.00 N 9.6 OO Israel A. Englander X1 0.00 128761.00 0.00 128761.00 128761.00 N 9.6 IN Sensei Biotherapeutics, Inc. 1405 Research Boulevard, Suite 125, Rockville, Maryland 20850 ICS Opportunities II LLC Millennium Management LLC Millennium Group Management LLC Israel A. Englander ICS Opportunities II LLC c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Management LLC 399 Park Avenue New York, New York 10022 Millennium Group Management LLC 399 Park Avenue New York, New York 10022 Israel A. Englander c/o Millennium Management LLC 399 Park Avenue New York, New York 10022 ICS Opportunities II LLC - Cayman Islands Millennium Management LLC - Delaware Millennium Group Management LLC - Delaware Israel A. Englander - United States Y See response to Item 9 on each cover page. As of the close of business on February 24, 2026, the reporting persons beneficially owned an aggregate of 84,541 shares of common stock, par value $0.0001 per share ("Common Stock") or 6.7% of the Common Stock outstanding. After acquiring beneficial ownership of more than 10% of the outstanding Common Stock on March 26, 2026, the reporting persons beneficially owned 127,095 shares of Common Stock or 10.1% of the Common Stock outstanding. As of the close of business on May 14, 2026, the reporting persons beneficially owned an aggregate of 128,761 shares of Common Stock or 9.6% of the Common Stock outstanding. The information reported on each cover page is as of the close of business on May 14, 2026. Calculations herein prior to May 14, 2026 are based on 1,261,290 shares of Common Stock outstanding as November 10, 2025, as reported by Sensei Biotherapeutics, Inc. (the "Company") on its 10-Q filed on November 14, 2025. Calculations as of May 14, 2026 are based on 1,341,140 shares of Common Stock outstanding as of April 13, 2026, as reported by the Company in the proxy statement filed on April 27, 2026. See response to Item 11 on each cover page. See response to Item 5 on each cover page. See response to Item 6 on each cover page. See response to Item 7 on each cover page. See response to Item 8 on each cover page. The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities. Y Y Y N See Exhibit I Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit I: Joint Filing Agreement, dated as of May 14, 2026, by and among ICS Opportunities II LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander. ICS Opportunities II LLC /s/ Gil Raviv 05/14/2026 Millennium Management LLC /s/ Gil Raviv 05/14/2026 Millennium Group Management LLC /s/ Gil Raviv 05/14/2026 Israel A. Englander /s/ Israel A. Englander 05/14/2026 ** ICS OPPORTUNITIES II LLC By: Millennium Management LLC, its Investment Manager